Evaxion Launches AI-Designed EVX-05 Brain Cancer Vaccine with Duke
EVAX sits 33% above its 52-week low of $2.52.
Summary
Evaxion announced a new off-the-shelf glioblastoma vaccine program, EVX-05, developed with Duke University. The program targets endogenous retrovirus antigens shared across patients, leveraging the AI-Immunology platform. The company also discontinued its EVX-03 program as part of portfolio refocusing. Costs for EVX-05 are within existing budgets, so cash runway guidance into H2 2027 is unchanged. Q2 results and business update are scheduled for August 20, where EVX-05 will be discussed.
At the time of this announcement, EVAX was trading at $3.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.9M. The 52-week trading range was $2.52 to $12.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.